drugset / Trial / NCT05642468
Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC).
Timeline
- Start
- 2023-01-09
- Primary completion
- 2025-07-10
- Completion
- 2025-07-10
Outcome
Outcome not reported
Stopped (Business): “Due to Sponsor decision, not due to any safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritivixibat | Small molecule | 10 mg | Oral |
| Subject | Ritivixibat | Small molecule | 30 mg | Oral |